Tharick A Pascoal
Overview
Explore the profile of Tharick A Pascoal including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
129
Citations
4059
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Kolobaric A, Andreescu C, Gerlach A, Jasarevic E, Aizenstein H, Pascoal T, et al.
Alzheimers Dement
. 2025 Mar;
21(3):e14493.
PMID: 40042417
Introduction: Late-life cognitive impairment and depression frequently co-occur and share many symptoms. However, the specific neural and clinical factors contributing to both their common and distinct profiles in older adults...
2.
Son S, Lee D, Roh H, Ly M, Kolobaric A, Aizenstein H, et al.
Alzheimers Res Ther
. 2025 Feb;
17(1):52.
PMID: 40016766
Background: Recent studies have focused on improving our understanding of gut microbiome dysbiosis and its impact on cognitive function. However, the relationship between gut microbiome composition, accelerated brain atrophy, and...
3.
Leffa D, Povala G, Bellaver B, Ferrari-Souza J, Ferreira P, Lussier F, et al.
Alzheimers Dement
. 2025 Feb;
21(2):e70003.
PMID: 39998851
Introduction: Epidemiological studies indicate a link between attention-deficit/hyperactivity disorder (ADHD) and elevated risk of dementia. However, the impact of ADHD on cognition and Alzheimer's disease (AD) biomarkers in individuals with...
4.
Islam T, Hill E, Abrahamson E, Servaes S, Smirnov D, Zeng X, et al.
Nat Med
. 2025 Feb;
31(2):574-588.
PMID: 39930142
Patients with Alzheimer's disease (AD) with little or no quantifiable insoluble brain tau neurofibrillary tangle (NFT) pathology demonstrate stronger clinical benefits of therapies than those with advanced NFTs. The formation...
5.
Da Ros L, Borelli W, Schaffer Aguzzoli C, De Bastiani M, Schilling L, Santamaria-Garcia H, et al.
Lancet Glob Health
. 2025 Jan;
13(2):e277-e284.
PMID: 39890228
Background: Latin American countries present major health-related inequities due to historical, cultural, and social aspects. Recent evidence highlights that factors related to social and health disparities outweigh classic demographic factors...
6.
Wang Y, Ashton N, Therriault J, Benedet A, Macedo A, Pola I, et al.
Brain Commun
. 2025 Jan;
7(1):fcaf004.
PMID: 39845736
Blood-based biomarkers have been revolutionizing the detection, diagnosis and screening of Alzheimer's disease. Specifically, phosphorylated-tau variants (p-tau, p-tau and p-tau) are promising biomarkers for identifying Alzheimer's disease pathology. Antibody-based assays...
7.
Nedelkov D, Tsokolas Z, Rodrigues M, Sible I, Han S, Kerman B, et al.
bioRxiv
. 2025 Jan;
PMID: 39763949
The apolipoprotein E ( ) ε4 allele is the strongest genetic risk factor for Alzheimer's disease (AD). ApoE is glycosylated with an O-linked Core-1 sialylated glycan at several sites, yet...
8.
Therriault J, Janelidze S, Benedet A, Ashton N, Arranz Martinez J, Gonzalez-Escalante A, et al.
Nat Aging
. 2024 Nov;
4(11):1529-1537.
PMID: 39533113
Recently approved anti-amyloid immunotherapies for Alzheimer's disease (AD) require evidence of amyloid-β pathology from positron emission tomography (PET) or cerebrospinal fluid (CSF) before initiating treatment. Blood-based biomarkers promise to reduce...
9.
Woo M, Therriault J, Jonaitis E, Wilson R, Langhough R, Rahmouni N, et al.
EBioMedicine
. 2024 Nov;
109():105413.
PMID: 39500009
Background: Blood-based disease staging across the Alzheimer's disease (AD) continuum holds the promise to identify individuals that profit from disease-modifying therapies. We set out to identify Braak V (Braak V...
10.
Aliaga A, Therriault J, Quispialaya K, Aliaga A, Hopewell R, Rahmouni N, et al.
J Nucl Med
. 2024 Oct;
66(1):123-129.
PMID: 39477493
Our objective was to evaluate the in vitro binding properties of [F]flortaucipir, 6-(fluoro-F)-3-(1-pyrrolo[2,3-c]pyridin-1-yl)isoquinolin-5-amine ([F]MK6240), and 2-(2-([F]fluoro)pyridin-4-yl)-9-pyrrolo[2,3-b:4,5c']dipyridine ([F]PI2620) head-to-head in postmortem human brain tissue. Autoradiography was used to assess uptake of...